Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 18 Nov 22 EFFECT Notice of effectiveness
- 16 Nov 22 POS AM Prospectus update (post-effective amendment)
- 11 Apr 22 424B5 Prospectus supplement for primary offering
- 7 Apr 22 424B5 Prospectus supplement for primary offering
- 18 Mar 22 424B5 Prospectus supplement for primary offering
- 11 Feb 21 424B5 Prospectus supplement for primary offering
- 20 Nov 20 424B5 Prospectus supplement for primary offering
- 19 Nov 20 424B5 Prospectus supplement for primary offering
- 6 Aug 20 424B5 Prospectus supplement for primary offering
- 13 Apr 20 EFFECT Notice of effectiveness
-
2 Apr 20 F-3 Shelf registration (foreign)
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in this Registration Statement onForm F-3 of our report dated April 1, 2020, relating to the consolidated financial statements of Stealth BioTherapeutics Corp appearing in the Annual Report on Form20-F for the year ended December 31, 2019. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
April 1, 2020